Akums gets approval for triple combination diabetes treatment

Pioglitazone, on the other hand, is an outstanding component as it is considered effective against T2D because of its ability to improve insulin sensitivity, lower HbA1c levels, and promote lipid metabolism and insulin secretion. The third component in the combination is Sitagliptin, which has been observed to significantly reduce HbA(1c) levels when used as an add-on therapy after the administration of insulin, sulfonylureas, or thiazolidinediones, or alone with or without metformin.

"We have carefully studied the pharmacological properties of these formulations and with Sitagliptin 100, Pioglitazone 15 and Metamorfin 1000/500, we found the right blend for our triple-active combination. This is going to better serve anti-diabetic patients who require better treatment without necessarily swallowing multiple drugs. The approval is a boost because it shows that we followed all laid down procedures, and the drug is fit for use by patients who need relief from the impacts of not just Type-2 diabetes, Patient convenience and dosage compliance " said Mr. Sanjeev Jain, Jt. Managing Director, Akums Drugs & Pharmaceuticals.

The bi-layered combination was formulated following well-researched processes and operations, as well as adherence to pharmacological guidelines. Speaking on the approval, Mr. Sandeep Jain, Jt. Managing Director, Akums Drugs & Pharmaceuticals, noted that the renoprotective effects of drugs like metformin coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome, and the stability of Sitagliptin, make an effective solution for diabetes. “As a brand, we will continue to introduce new combinations to help patients around the world get better," he added.

Read also: Akums Gets CDSCO panel Nod To Manufacture, Market Bisoprolol Fumarate